Favorable outcome in children and adolescents with a high proportion of advanced phase disease using single/multiple autologous or matched/mismatched allogeneic stem cell transplantations
| العنوان: | Favorable outcome in children and adolescents with a high proportion of advanced phase disease using single/multiple autologous or matched/mismatched allogeneic stem cell transplantations |
|---|---|
| المؤلفون: | Holger Christiansen, Dieter Körholz, Wolfram Ebell, Gerhard Behre, Vladan Vucinic, Sven Starke, Peter Bader, Juliane Beck, Simone Heyn, Thoralf Lange, R. Krahl, Georg-Nikolaus Franke, Ann-Kathrin Eisfeld, Christian Niederwieser, Michael Cross, Wilhelm Wößmann, L. Fischer, B. Gruhn, Wolfram Pönisch, Peter Lang, Haifa Kathrin Al-Ali |
| المصدر: | Annals of Hematology. 95:473-481 |
| بيانات النشر: | Springer Science and Business Media LLC, 2015. |
| سنة النشر: | 2015 |
| مصطلحات موضوعية: | Male, medicine.medical_specialty, Transplantation Conditioning, Adolescent, medicine.medical_treatment, Hematopoietic stem cell transplantation, Young Adult, 03 medical and health sciences, 0302 clinical medicine, hemic and lymphatic diseases, Internal medicine, medicine, Humans, Transplantation, Homologous, Young adult, Stage (cooking), Child, Survival rate, Hematology, Framingham Risk Score, business.industry, Incidence (epidemiology), Hematopoietic Stem Cell Transplantation, Infant, General Medicine, Surgery, Survival Rate, Treatment Outcome, surgical procedures, operative, Child, Preschool, Hematologic Neoplasms, 030220 oncology & carcinogenesis, Female, business, Follow-Up Studies, 030215 immunology |
| الوصف: | We determined the indication, outcome, and risk factors of single and multiple hematopoietic stem cell transplantation(s) (HSCT) in children and adolescents mostly with advanced disease. Forty-one out of 483 patients (8.5 %; median age 9 years) diagnosed at the University of Leipzig with hematological and oncological diseases required HSCT from 1999 to 2011. Patients had overall survival (OS) of 63 ± 10 and 63 ± 16 %, event-free survival (EFS) of 57 ± 10 and 42 ± 16 %, relapse incidence (RI) of 39 ± 10 and 44 ± 18 % and nonrelapse mortality (NRM) of 4 ± 4 and 13 ± 9 % at 10 years after one or more allogeneic and autologous HSCT, respectively. One patient in CR1 and five with advanced disease received two HSCT. Four of the six patients maintained/achieved CR for a median of 13 months. Three died of progression and one of NRM. Two patients had a third HSCT and one survived in CR +231 days after HSCT. Risk factors for OS and EFS were disease stage at HSCT and EBMT risk score. Center (pediatric or JACIE accredited pediatric/adult) was not a determinant for survival. Pediatric single and multiple HSCT are important curative approaches for high-risk malignant diseases with low NRM. Efforts to reduce high RI remain the major aim. |
| تدمد: | 1432-0584 0939-5555 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17c0c4b9f5f8401bf013c426841df0c6Test https://doi.org/10.1007/s00277-015-2569-7Test |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....17c0c4b9f5f8401bf013c426841df0c6 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14320584 09395555 |
|---|